As global capital markets waver under the dual pressures of resurgent inflation and geopolitical conflicts, hedge fund titan Ken Griffin’s first-quarter portfolio adjustment has pointed a clear direction for risk-averse investors. The founder of Citadel, which oversees $69 billion in assets, increased his stake in Johnson & Johnson (JNJ) by a whopping 146% in the first quarter of this year, bringing his total holdings to approximately 1.93 million shares. Though the position accounts for just 0.08% of his portfolio, the fact that he has held it continuously since 2017 suggests Griffin views J&J as a long-term winner capable of weathering market cycles.
For risk-averse investors, J&J’s appeal is rooted first and foremost in its clear strategic focus. A few years ago, the company decisively spun off its consumer health business into the separately listed Kenvue, allowing it to channel all resources into its two core growth engines: innovative pharmaceuticals and medtech. The results have validated this strategic pivot—the latest earnings report shows innovative medicine sales jumped 11% year-over-year, medtech sales advanced more than 7%, and overall worldwide revenue grew nearly 10% to approach $24 billion. Shedding low-growth businesses and concentrating resources on high-barrier sectors—this strategic clarity itself is the first step in reducing uncertainty.
What further reassures investors is that J&J’s growth does not rely on one or two “blockbuster” products. The company currently boasts 28 platforms or products generating at least $1 billion in annual sales, and that number continues to grow. This diversified portfolio of heavyweight products builds a robust defensive moat—when one product faces patent expiration or intensifying competition, others are more than capable of filling the gap.
The most telling example comes from immunology blockbuster Stelara: despite a 41% plunge in Stelara sales last year, the company held its ground, powered by the strong performance of other key drugs, and still delivered 6% total revenue growth for the full year. Management even stated that the loss of exclusivity has been placed “in the rearview mirror.” For investors, this kind of business resilience—where weakness in one area is offset by strength in another—is the very essence of low-risk investing.
J&J’s second major draw lies in its undisputed status as a Dividend King—the company has increased its dividend payout for more than 50 consecutive years. In volatile markets, this half-century-plus record of uninterrupted dividend growth is not only a powerful testament to its shareholder return commitment but also hard proof of financial health. Currently, J&J pays an annual dividend of $5.36 per share, representing a dividend yield of approximately 2%, significantly above the S&P 500’s average of 1.1%. And underpinning the sustainability of these payouts is the company’s abundant free cash flow—even when the external environment is under pressure, the essential nature of medical products ensures stable cash inflows.
Looking at the broader macroeconomic landscape, global growth momentum is weakening and inflation trends remain erratic, driving unprecedented demand for assets with certainty. Ken Griffin’s stake increase is, at its core, a vote of confidence—backed by real capital—in J&J’s “defensive growth” thesis. For investors seeking steady returns and who prefer to avoid the turbulence of market swings, J&J—with its combination of business resilience and consistent dividends—undoubtedly offers a reassuring prescription.
